FULGENT GENETICS, INC. Business Acquisition, Pro Forma Revenue
FULGENT GENETICS, INC. (FLGT) reported Business Acquisition, Pro Forma Revenue of $84.62 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-01.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-05-01
- FULGENT GENETICS, INC. business acquisition, pro forma revenue for the quarter ending 2026-03-31 was $84.62M, a 6.61% decline year-over-year.
- FULGENT GENETICS, INC. business acquisition, pro forma revenue for the quarter ending 2025-09-30 was $84.05M, a 17.44% increase year-over-year.
- FULGENT GENETICS, INC. business acquisition, pro forma revenue for the quarter ending 2025-03-31 was $90.61M.
- FULGENT GENETICS, INC. business acquisition, pro forma revenue for the quarter ending 2024-09-30 was $71.57M.
- FULGENT GENETICS, INC. business acquisition, pro forma revenue for fiscal 2022 was $659.39M, a 2644.93% increase from fiscal 2021.
- FULGENT GENETICS, INC. business acquisition, pro forma revenue for fiscal 2021 was $24.02M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|
| 2026-03-31 | $84.62M 10-Q · filed 2026-05-01 | ||
| 2025-09-30 | $84.05M 10-Q · filed 2025-11-07 | $249.99M 10-Q · filed 2025-11-07 | |
| 2025-03-31 | $90.61M 10-Q · filed 2026-05-01 | ||
| 2024-09-30 | $71.57M 10-Q · filed 2025-11-07 | $217.51M 10-Q · filed 2025-11-07 | |
| 2022-12-31 | $659.39M 10-K · filed 2025-02-28 | ||
| 2021-12-31 | $12.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $24.02M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $11.66M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |